RECRUITINGINTERVENTIONAL
Cerebellar tDCS in Children With Autism Spectrum Disorder
Biologic Effects and Efficacy of Cerebellar tDCS in Children With Autism Spectrum Disorder
About This Trial
The purpose of this research study is to investigate whether tDCS to the cerebellum (specifically, the right crus I/II area of the cerebellum) of children and young adults with autism spectrum disorders (ASD) is safe and to examine its effects on some of the symptoms of ASD, such as repetitive behaviors and hyperactivity.
Who May Be Eligible (Plain English)
Who May Qualify:
- 4-17 years old
- Diagnosed with ASD and ADOS-2
- IQ Score no less than 70 (1.5 Standard Deviations below the mean)
- Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences)
Who Should NOT Join This Trial:
- Brain implants, metal implants, pacemakers, or biomedical devices
- Diagnosis of epilepsy
- Hearing or visual impairments
- History of brain injury
- Known brain abnormalities not associated with ASD
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 4-17 years old
* Diagnosed with ASD and ADOS-2
* IQ Score no less than 70 (1.5 Standard Deviations below the mean)
* Language Level (Speech consists of, at minimum, flexible, spontaneous, simple, sentences)
Exclusion Criteria:
* Brain implants, metal implants, pacemakers, or biomedical devices
* Diagnosis of epilepsy
* Hearing or visual impairments
* History of brain injury
* Known brain abnormalities not associated with ASD
Treatments Being Tested
DEVICE
tDCS
A current of 1 mA will be administered for 20 minutes of with either anodal or cathodal tDCS administration to the right crus I/II area of the cerebellum.
Locations (2)
Children's Medical Center
Dallas, Texas, United States
University of Texas Southwestern
Dallas, Texas, United States